Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments

Published on: February 7, 2025

Comprehensive Genomic Profiles of Patients With Biliary Tract Cancer.

Xia Yang^1,2, Tao Zhu¹, Xiaotong Hu¹

¹Department of Pathology, Sir Run Run Shaw Hospital of Zhejiang University, Zhejiang, Hangzhou, China.

Cancer Medicine

|June 13, 2026

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Integrative multi-omics and single-cell analysis identifies EGFR pathway activation and metabolic reprogramming as potential synthetic lethal vulnerabilities in resistance to the FGFR inhibitor AZD4547.

Journal of translational medicine·2026

Same author

Nucleic Acid Therapeutics for "Undruggable" Cancer Targets: Mechanisms, Challenges, and Prospects.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

PIAS4 inhibition induces cell cycle arrest and exhibits a synergistic effect in combination with CDK4/6 inhibitor in breast cancer treatment.

Oncogene·2026

Same author

Targeting WIP1 reprograms immunosuppressive tumor microenvironment to potentiate immunotherapy response in colorectal cancer.

Cell death and differentiation·2026

Same author

Nonsense-mediated mRNA decay inhibits TRAF6-dependent anti-tumor immunity in colorectal cancer.

Cell reports. Medicine·2025

Same author

SH3BGRL2 as a vital tumor suppressor and prognostic factor in human esophageal squamous cell carcinoma.

Journal of thoracic disease·2025

Genomic analysis of 134 biliary tract cancer (BTC) patients revealed frequent TP53 and KRAS alterations. These findings, including differences between Chinese and Western BTCs, may guide precision medicine development for this lethal cancer.

Area of Science:

Oncology
Genomics
Precision Medicine

Background:

Biliary tract cancer (BTC) is a lethal malignancy with poor outcomes.
Understanding its genomic landscape is crucial for advancing precision medicine.

Purpose of the Study:

To evaluate the genomic profiles of BTC patients.
To identify potential targets for precision medicine in BTC.

Main Methods:

Targeted panel sequencing of 134 BTC patients.
Integration of clinicopathologic data and clinical outcomes.
Comparison with Western BTCs using ICGC cohort NGS data.

Main Results:

Frequent alterations: TP53 (55.5%), KRAS (38.1%), ARID1A (17.2%), CDKN2A (15.7%).

Keywords:

biliary tract cancer prognosis targeted next‐generation sequencing

Related Experiment Videos

Last Updated: Jun 14, 2026

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments

Published on: February 7, 2025

Chinese BTC patients showed higher TP53, KRAS, and LRP1B alterations than Western counterparts.

Specific alterations correlated with survival outcomes; TP53 associated with inferior outcomes in both populations.

Conclusions:

Real-world genomic data offer insights for BTC precision medicine.
Prospective studies are needed to validate the predictive role of identified genomic alterations.